Nuveen Asset Management LLC Has $8.21 Million Position in Bioventus Inc. (NYSE:BVS)

Nuveen Asset Management LLC raised its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 20.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 782,137 shares of the company's stock after acquiring an additional 135,236 shares during the quarter. Nuveen Asset Management LLC owned about 0.96% of Bioventus worth $8,212,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Tower Research Capital LLC TRC raised its holdings in Bioventus by 106.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock worth $36,000 after buying an additional 1,786 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Bioventus during the fourth quarter worth $38,000. KLP Kapitalforvaltning AS bought a new stake in Bioventus in the 4th quarter valued at $75,000. Quantbot Technologies LP acquired a new position in Bioventus in the 4th quarter worth $103,000. Finally, Arizona State Retirement System bought a new position in Bioventus during the 4th quarter worth about $109,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Stock Down 0.3%

Shares of NYSE BVS traded down $0.02 during mid-day trading on Friday, hitting $6.54. The company had a trading volume of 316,084 shares, compared to its average volume of 454,351. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a 50-day simple moving average of $7.47 and a two-hundred day simple moving average of $9.46. The company has a market capitalization of $537.22 million, a PE ratio of -10.72 and a beta of 0.95. Bioventus Inc. has a one year low of $5.28 and a one year high of $14.38.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BVS shares. Craig Hallum set a $15.00 price objective on Bioventus and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th.

Insider Buying and Selling

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at $1,068,036.16. This represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders sold 13,330 shares of company stock worth $115,291. Company insiders own 32.90% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.